Novartis has teamed up with a UK fund manager and the Cancer Research UK Beatson Institute in Glasgow to develop RAS inhibitors for difficult-to-treat cancers. RAS is a family of genes that make proteins involved in cell signalling pathways that control cell growth and death. It is estimated that more than 30% of all human cancers, including 95% of pancreatic cancers and 45% of colorectal cancers are driven by mutations of the RAS gene family.
